Liraglutide Cost in Connecticut 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Liraglutide Actually Cost in Connecticut in 2026?

The manufacturer list price for liraglutide sits at roughly $1,349 per month, but almost nobody pays that figure at the pharmacy counter. Connecticut retail pharmacies averaged around $900 per month for cash-paying patients in 2026, depending on the pen formulation, dose strength, and specific pharmacy chain. Patients with commercial insurance, Medicaid, or access to a manufacturer savings card pay considerably less.

Liraglutide is sold under two brand names by Novo Nordisk: Victoza (1.2 mg and 1.8 mg, indicated for type 2 diabetes and cardiovascular risk reduction) and Saxenda (3.0 mg, indicated for chronic weight management). Both are subcutaneous injection pens dosed once daily. The FDA approved Victoza in January 2010 and Saxenda in December 2014. [1][2] As of mid-2025, no FDA-approved generic liraglutide tablet or injection has reached the U.S. Market, meaning branded pricing still governs the retail field.

The SCALE Obesity and Prediabetes trial (N=3,731) published in the New England Journal of Medicine demonstrated that liraglutide 3.0 mg produced a mean weight loss of 8.4 kg over 56 weeks compared with 2.8 kg in the placebo group (P<0.001). [3] That clinical outcome underlies the widespread prescriber interest that keeps demand, and therefore price pressure, elevated in Connecticut.

Understanding exactly where you fall on the price spectrum requires knowing your insurance tier, whether your prescriber has documented the required criteria, and whether a compounding option is medically and legally appropriate for your situation. [4]

Connecticut Medicaid Coverage for Liraglutide

Connecticut Medicaid (HUSKY Health) covers liraglutide for both type 2 diabetes and chronic weight management indications, subject to prior authorization (PA). PA is not automatic, and the requirements differ by indication.

For the diabetes indication (Victoza), the Connecticut Medicaid preferred drug list generally requires documentation of a hemoglobin A1c at or above a threshold, confirmation that the prescriber has tried at least one first-line agent such as metformin, and a diagnosis of type 2 diabetes supported by ICD-10 coding. The American Diabetes Association 2024 Standards of Care list GLP-1 receptor agonists as a preferred add-on therapy in patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, which can strengthen a PA request. [5]

For the obesity indication (Saxenda), PA criteria typically require a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnea, mirroring the FDA label criteria. [6] Documentation of a structured lifestyle intervention attempt is usually required as well.

The SCALE Insulin trial (N=396) showed that adding liraglutide 1.8 mg to insulin degludec produced a statistically greater reduction in A1c than insulin alone (mean difference 0.53%, P<0.001), which may support PA arguments for patients already on insulin. [7] If your PA is denied, Connecticut Medicaid permits a formal appeal process; your prescriber's office can submit a peer-to-peer review with the plan's medical director within 30 days of denial.

Commercial Insurance Coverage in Connecticut

Most major commercial plans operating in Connecticut place liraglutide on Tier 3 or Tier 4 of their formulary, which corresponds to specialty or preferred brand copays. Anthem, Aetna, UnitedHealthcare, and Cigna all offer plans in Connecticut that list one or both liraglutide formulations, though formulary tier assignment changes annually during open enrollment.

A 2023 analysis published in JAMA Health Forum found that GLP-1 receptor agonist coverage varied substantially across commercial plan types, with employer-sponsored plans more likely to cover obesity-indicated GLP-1 agents than individual marketplace plans. [8] Connecticut's state insurance exchange (Access Health CT) offers plans that may or may not include Saxenda coverage depending on the specific carrier and tier.

Typical out-of-pocket costs after insurance range from $25 to $150 per month on plans with a Tier 3 specialty copay structure, assuming the deductible has been met. Before the deductible, patients may pay the full negotiated rate, which can be several hundred dollars. Checking your plan's formulary on the carrier's website or calling the pharmacy benefits number on your insurance card before the prescription is filled saves significant confusion.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Pharmacological treatment of obesity should be considered as an adjunct to lifestyle intervention in patients who do not achieve adequate weight loss through lifestyle measures alone." [9] Citing this guideline in a letter of medical necessity can support coverage appeals for Saxenda when a plan initially denies the claim.

Compounded Liraglutide in Connecticut: Legality and Practical Access

Compounded liraglutide from a 503A pharmacy is legal in Connecticut under current state pharmacy board rules. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed practitioner. The key distinctions from FDA-approved Saxenda or Victoza are significant: compounded preparations are not FDA-approved, they are not bioequivalence-tested against the brand, and quality control standards vary by compounding pharmacy. [10]

In Connecticut, the cost for compounded liraglutide through a licensed 503A pharmacy runs approximately $150 per month in 2026, compared with the $900 average retail cash price for the branded pen. That price difference is real and often decisive for patients without insurance coverage for the brand. However, the FDA has warned repeatedly about risks associated with compounded GLP-1 medications, including potential dosing errors and variability in active pharmaceutical ingredient quality. [11]

The FDA's 2024 guidance on compounded semaglutide and related GLP-1 agents clarified that a drug may only be compounded under section 503A if the bulk drug substance is on the FDA's "503A bulks list" or is part of an active shortage designation. [12] Liraglutide does not appear on the current FDA shortage list as of mid-2025, which means 503A compounding of liraglutide occupies a legally ambiguous position at the federal level even when a state's pharmacy board permits it. Patients should ask their prescriber and their compounding pharmacy for documentation of the legal basis before proceeding.

A Connecticut-licensed prescriber must write a patient-specific prescription. Telehealth prescribers operating in Connecticut can issue this prescription if they hold a valid Connecticut DEA registration and the consultation meets Connecticut telemedicine prescribing standards. [13]

Telehealth Prescribing of Liraglutide in Connecticut

Connecticut permits telehealth prescribing of non-controlled prescription medications, and liraglutide is not a scheduled controlled substance. A licensed prescriber with Connecticut prescribing authority can evaluate a patient via synchronous video or audio and issue a liraglutide prescription without an in-person visit, as long as the clinical encounter meets the standard of care for the indication.

Connecticut's telehealth statute (C.G.S. Section 19a-906) requires that telehealth services meet the same standard of care as in-person services. [14] For liraglutide prescribing, this means the prescriber must document indication (type 2 diabetes or obesity), weight, BMI, comorbidities, contraindications (personal or family history of medullary thyroid carcinoma or MEN 2 syndrome), and patient education on injection technique and side effects.

A systematic review in The Lancet Digital Health (2021) covering 32 randomized controlled trials found that telehealth-delivered weight management interventions produced comparable weight loss outcomes to in-person programs at 12 months. [15] Combined with a GLP-1 medication like liraglutide, telehealth-based management may be a practical option for Connecticut patients in rural counties or those without nearby endocrinology or obesity medicine specialists.

Once the prescription is written, it can be sent to any Connecticut retail pharmacy or a mail-order pharmacy licensed to operate in Connecticut.

Novo Nordisk Savings Programs and Patient Assistance in Connecticut

Novo Nordisk offers two programs that Connecticut patients may access:

The Novo Nordisk Patient Assistance Program provides Victoza or Saxenda at no cost to qualifying uninsured or underinsured patients whose household income falls at or below 400% of the federal poverty level. Applications go through NovoCare and require income verification and confirmation of insurance status. [16]

The Victoza Savings Card and Saxenda Savings Card (for commercially insured patients) reduce out-of-pocket costs to as low as $25 per 30-day supply for eligible patients. These savings cards are not available to patients enrolled in Medicare, Medicaid, or any federal or state government health program. Connecticut patients on HUSKY Health are therefore ineligible for the manufacturer savings card, though they may qualify for the patient assistance program instead. [17]

The table below outlines the four primary access pathways for Connecticut patients in 2026, organized by monthly cost estimate:

| Access Pathway | Estimated Monthly Cost (CT, 2026) | Key Requirement | |---|---|---| | Compounded liraglutide (503A pharmacy) | ~$150 | Valid CT prescription; legal status should be verified | | Novo Nordisk patient assistance | $0 | Income at or below 400% FPL; uninsured or underinsured | | Connecticut Medicaid (HUSKY Health) | $0 to nominal copay | Prior authorization approval | | Commercial insurance (Tier 3 copay, deductible met) | $25 to $150 | Formulary coverage; PA if required | | Manufacturer savings card (commercial only) | as low as $25 | Cannot be combined with government insurance | | Retail cash price (CT pharmacies) | ~$900 | No insurance or savings programs involved |

Clinical Efficacy: What the Evidence Shows for Liraglutide

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and reduces appetite through central hypothalamic pathways. These mechanisms produce effects on both glycemia and body weight, which explains its dual approval.

The SCALE Obesity trial (N=3,731) published in the New England Journal of Medicine in 2015 is the foundational weight-management study. Liraglutide 3.0 mg produced a mean weight loss of 8.4 kg at 56 weeks; 63.2% of participants lost at least 5% of body weight versus 27.1% on placebo (P<0.001). [3] The LEADER trial (N=9,340) demonstrated that liraglutide 1.8 mg reduced the primary composite cardiovascular endpoint (MACE) by 13% relative to placebo in patients with type 2 diabetes and high cardiovascular risk, with a hazard ratio of 0.87 (95% CI 0.78 to 0.97, P=0.01 for superiority). [18]

The SCALE Diabetes trial (N=846) showed that liraglutide 3.0 mg produced a 6.0% mean weight loss at 56 weeks in patients with type 2 diabetes, compared with 2.0% on placebo, alongside a mean A1c reduction of 1.33% versus 0.38% (P<0.001 for both). [19]

Common adverse effects include nausea (40% of patients in SCALE Obesity, typically transient), vomiting, diarrhea, and constipation. The liraglutide FDA label carries a boxed warning for thyroid C-cell tumors observed in rodent studies; the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. [20]

The American Association of Clinical Endocrinology 2023 obesity guidelines recommend GLP-1 receptor agonists as first-line pharmacotherapy for patients meeting BMI criteria, citing liraglutide as a Level A evidence option. [21]

Dosing Protocol for Liraglutide in Connecticut Patients

The titration schedule for liraglutide is identical whether the prescription comes from a Connecticut endocrinologist, primary care physician, or telehealth provider:

For Saxenda (weight management): Start at 0.6 mg subcutaneously once daily for week 1, increase to 1.2 mg in week 2 to 1.8 mg in week 3 to 2.4 mg in week 4, and reach the full therapeutic dose of 3.0 mg by week 5. The slow escalation reduces nausea and gastrointestinal side effects. [2]

For Victoza (type 2 diabetes): Start at 0.6 mg once daily for at least one week, increase to 1.2 mg, then to 1.8 mg if additional glycemic control is needed. [1]

The American Diabetes Association 2024 Standards of Care recommend reassessing response at 16 weeks for obesity-indicated GLP-1 therapy. If a patient has not lost at least 4% of initial body weight on the maximum tolerated dose by that point, the therapy should be reconsidered. [5] For Connecticut Medicaid patients, documenting this reassessment protects against subsequent PA renewal denials.

Injection sites include the abdomen, thigh, or upper arm. Liraglutide pens do not require refrigeration after first use (stable at room temperature up to 30 degrees C for 30 days), which simplifies storage for patients traveling or working long hours.

How Connecticut Compares to National Liraglutide Pricing

Connecticut's average cash retail price of approximately $900 per month is modestly above the national average of roughly $850 to $875 per month for branded liraglutide pens in 2026, likely reflecting the state's higher general cost of living and pharmacy overhead. A 2022 JAMA Internal Medicine analysis of GLP-1 drug pricing across 50 states found that Northeast states consistently ranked in the top quartile for retail drug costs compared with South-Central states. [22]

The gap between the $1,349 list price and the $900 average cash price reflects pharmacy benefit manager rebate structures and direct-to-consumer discount negotiations. Patients using GoodRx or similar discount platforms may find prices at specific Connecticut pharmacies ranging from $800 to $1,100 per month for Saxenda depending on the pen count in the prescription. [23]

For context, semaglutide (Ozempic 0.5 mg to 2 mg for diabetes, Wegovy 2.4 mg for obesity) lists at approximately $935 to $1,349 per month, placing liraglutide at a similar or slightly higher price point depending on formulation. A 2024 Health Affairs study found that among commercially insured patients, out-of-pocket costs for GLP-1 receptor agonists averaged $53 per month after insurance, but that figure masked substantial variation depending on deductible phase. [24]

Prior Authorization Strategy for Connecticut Prescribers and Patients

Getting liraglutide covered quickly in Connecticut depends on the completeness of the initial PA submission. Missing a single required document, such as a BMI measurement recorded within the prior 12 months or documentation of a lifestyle intervention, is the most common reason for initial denials.

A structured PA checklist for Connecticut prescribers should include: current weight and BMI (dated within 6 to 12 months), relevant ICD-10 codes (E11.x for type 2 diabetes, E66.x for obesity), documentation of contraindication screening (thyroid history, pancreatitis history), records of prior therapy trials where required by the specific plan, and a brief statement of medical necessity referencing the appropriate guideline. [25]

The American Gastroenterological Association's 2022 rapid review on GLP-1 receptor agonists noted that liraglutide's clinical benefit in reducing hepatic steatosis may provide an additional medically necessary indication for some patients with concurrent metabolic-associated fatty liver disease (MAFLD), potentially strengthening a PA narrative. [26]

If a PA is denied, Connecticut law (C.G.S. Section 38a-591e) requires insurers to provide a written explanation of denial and inform patients of their appeal rights within specific timeframes. An expedited appeal is available when a standard timeframe would seriously jeopardize health. [27]

What to Ask Your Connecticut Telehealth or In-Person Prescriber

Patients preparing for a liraglutide consultation in Connecticut should come with specific information ready: current weight and height (for BMI calculation), a list of current medications (particularly any other diabetes or weight medications), personal and family history related to thyroid cancer or endocrine tumors, and documentation of any prior weight loss medications tried.

Ask your prescriber these four specific questions before leaving the appointment:

1. Which formulation are you prescribing, Victoza or Saxenda, and why?
2. What is the prior authorization plan if my insurance requires one?
3. Is a 503A compounded liraglutide prescription appropriate and legally supportable for my specific situation?
4. What is the reassessment timeline, and what weight loss benchmark should I expect to hit before you consider an adjustment?

A meta-analysis of 17 randomized trials (N=5,813) published in Obesity Reviews in 2021 found that GLP-1 receptor agonists combined with behavioral intervention produced 4.2 kg more weight loss than behavioral intervention alone at 12 months, confirming that liraglutide works best alongside structured diet and activity changes rather than as a standalone therapy. [28]

Connecticut residents can access board-certified obesity medicine physicians through the Obesity Medicine Association's provider directory, or reach endocrinologists accepting new patients through the Endocrine Society's member directory. Telehealth platforms licensed in Connecticut must employ prescribers with active Connecticut medical licenses or reciprocity arrangements. [29]